Skip to main content
Log in

Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone

  • Short Communication
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Tyrosinemia type I is an autosomal recessively inherited metabolic disease of tyrosine metabolism due to the deficiency of fumarylacetoacetate hydrolase. Clinical manifestations include hepatic failure, cirrhosis, hepatocellular carcinoma, renal fanconi syndrome, and neurologic crisis. With the introduction of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione treatment the prognosis improved with reduced rate of complications. “Neurologic crisis” of tyrosinemia type I is a rare complication seen after discontinuation of treatment characterized with anorexia, vomiting, and hyponatremia in the initial phase continuing with paresthesia and paralysis of the extremities and the diaphragm. Here, we report a tyrosinemia type I patient who admitted to the hospital with nonspecific symptoms such as vomiting, anorexia, weakness, and restlessness only after one month discontinuation of nitisone and diagnosed as neurological crisis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Counce ML, Dalmau J, del Toro M, et al. (2011) Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int 53:985–989

    Article  Google Scholar 

  • Jamieson GN, Jamieson N, Clayton P, Bailey S, Ryalls M, Barnes ND (1994) Neurological crisis in hereditary tyrosinaemia and complete reversal after liver transplantation. Arch Dis Child 70:544–545

    Article  PubMed  PubMed Central  Google Scholar 

  • Larochelle J, Alvarez F, Bussieres JF, et al. (2012) Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 107:49–54

    Article  CAS  PubMed  Google Scholar 

  • Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817

    Article  CAS  PubMed  Google Scholar 

  • Nyhan WL, Barshop BA, Al-Aqeel AI (2012) Hepatorenal tyrosinemia/fumarylacetoacetate hydrolase deficiency. In: WL N, BA B, AI A-A (eds) Atlas of inherited metabolic diseases, Third edn. Hodder Arnold an Hachette UK Company, London, pp. 171–179

    Google Scholar 

  • Rank JM, Pascual-Leone A, Payne W, et al. (1991) Clinical and laboratory observations. Hematin therapy for the neurologic crisis of tyrosinemia. J Pediatr 118:136–139

    Article  CAS  PubMed  Google Scholar 

  • Schlump JU, Perot C, Ketteler K, et al. (2008) Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis 31(2):223–225

    Article  Google Scholar 

  • Zeybek AC, Kiykim E, Soyucen E, et al. (2015) Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int 57:281–289

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Neslihan Önenli Mungan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Önenli Mungan, N., Yıldızdaş, D., Kör, D. et al. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone. Metab Brain Dis 31, 1181–1183 (2016). https://doi.org/10.1007/s11011-016-9833-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-016-9833-y

Keywords

Navigation